ERBB2 and breast cancer: Here, we report the development and characterization of eight novel human breast cancer patient-derived xenografts (BM-PDXs) from ER+, HER2+, and TN subtypes and a matching TN cell line, which retain tumor heterogeneity and brain metastatic potential.